Teva Pharmaceuticals USA

Teva Pharmaceuticals USA is the United States operating business associated with Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company best known for generic medicines and an expanding specialty-medicines portfolio. The U.S. business is headquartered in Parsippany, New Jersey, and serves one of the world's largest and most commercially important pharmaceutical markets. The business should not be understood solely as an over-the-counter medicines label. Its principal U.S. activities have historically centered on prescription generic drugs, including oral solid medicines, injectable products, respiratory treatments, and other dosage forms. Teva also markets specialty medicines in areas such as multiple sclerosis, migraine, respiratory disease, movement disorders, and central nervous system conditions. Some Teva consumer-health and nonprescription products have been sold in the United States, but the company's identity and commercial scale are primarily tied to prescription pharmaceuticals and generic competition. Teva's U.S. presence developed alongside the parent company's international growth. Teva established a substantial American platform through organic expansion, acquisitions, manufacturing, regulatory capabilities, and relationships with wholesalers, pharmacy operators, hospitals, health systems, and public and private insurers. The U.S. business has been important to Teva's global revenue base, while also exposing the company to intense price competition, product litigation, drug-shortage concerns, regulatory scrutiny, and pressure from pharmacy-benefit and purchasing organizations. A major strategic turning point was Teva's acquisition of Actavis Generics from Allergan in 2016. The transaction greatly increased Teva's generic portfolio and global scale, including its U.S. presence, but also contributed to a heavier debt burden and intensified the company's subsequent restructuring. In response, Teva pursued cost reductions, portfolio prioritization, divestitures, debt reduction, and greater emphasis on specialty medicines and selected innovative products. Teva Pharmaceuticals USA remains an active pharmaceutical business rather than a standalone publicly traded company. Its public-company status derives from its parent, Teva Pharmaceutical Industries Ltd., which is listed in the United States and Israel. Product availability, branding, and regulatory status vary by medicine and market; therefore, individual U.S. products should be checked against current company information and U.S. Food and Drug Administration records.

Teva Pharmaceuticals USA forms part of the American operating structure of Teva Pharmaceutical Industries Ltd. Teva's global history began in Israel, where the company developed from a local pharmaceutical distributor into an international medicines manufacturer and marketer. Its expansion was driven especially by generic pharmaceuticals, a field in which regulatory approvals, manufacturing capacity, broad product portfolios, and distribution scale are central competitive advantages. The United States became a major market for Teva through direct commercial operations, manufacturing and development capabilities, acquisitions, and partnerships. The company built a broad U.S. generic business serving retail pharmacies, wholesalers, hospitals, health systems, and other institutional customers. Its portfolio has included tablets, capsules, injectables, respiratory products, and other dosage forms. Teva has also marketed branded and specialty therapies in the United States, creating a business mix that extends beyond conventional generic medicines. Teva's U.S. position expanded significantly through acquisitions. The most consequential recent transaction was the 2016 purchase of Actavis Generics from Allergan. The deal made Teva one of the world's largest generic-drug companies and materially increased its presence across multiple therapeutic categories and markets. However, the acquisition also left the parent company with substantial debt at a time when generic-drug pricing was under pressure. Teva subsequently undertook a major restructuring involving workforce reductions, manufacturing and facility changes, portfolio reviews, divestitures, and a sharper focus on debt reduction and selected specialty products. In the specialty area, Teva's U.S. business has been associated with medicines including Copaxone for multiple sclerosis, Ajovy for migraine prevention, and Austedo for certain movement disorders. It has also maintained a role in respiratory medicines, including products marketed under the ProAir name at different points in the product portfolio. The precise products available in the United States change as patents expire, generic competition develops, regulatory approvals are granted or withdrawn, and commercial rights are transferred. The U.S. pharmaceutical market has also brought legal and regulatory challenges. Teva has faced litigation and government scrutiny relating to generic-drug competition, product liability, pricing and marketing practices, and opioids. In 2022 and subsequent years, the company reached broad settlement arrangements with U.S. states and local governments over opioid-related claims. The settlements represented a significant legal and reputational event for the company, while Teva stated that the agreements did not constitute an admission of wrongdoing. Today, Teva Pharmaceuticals USA is best described as a U.S. corporate operating business rather than an independent listed company or a purely OTC brand. It operates under the broader Teva group, whose strategic priorities include sustaining a large generic portfolio, expanding selected specialty and innovative medicines, managing manufacturing and supply reliability, and improving financial resilience. Because the business spans prescription, specialty, hospital, respiratory, and selected consumer-health products, its market identity differs from the narrower OTC classification supplied in the original brief.

1. 2022Nationwide opioid settlement framework

   Teva entered a framework for resolving extensive U.S. opioid litigation through payments and in-kind medicine commitments.

   Source
2. 2020Teva expands COVID-19 response activities

   Teva described manufacturing, supply, donation, and research-related activities connected with the COVID-19 pandemic.

   Source
3. 2017Global restructuring announced

   Teva announced a major restructuring and cost-reduction plan following portfolio expansion, pricing pressure, and increased leverage.

   Source
4. 2016Actavis Generics acquisition completed

   Teva completed the purchase of Allergan's Actavis Generics business, significantly increasing its global generic-drug scale and U.S. portfolio.

   Source

A large U.S. pharmaceutical supplier combining broad generic-drug coverage with selected specialty and innovative medicines, with an emphasis on access, scale, and cost-conscious treatment options.

• Generic medicinesGeneric pharmaceuticals

  Teva's U.S. generic portfolio covers numerous therapeutic areas and dosage forms, including oral solid medicines, injectables, respiratory products, and hospital-use medicines. Products enter or leave the portfolio as patents expire, abbreviated new drug applications are approved, manufacturing arrangements change, and commercial priorities are revised.

• CopaxoneMultiple sclerosis therapy

  Copaxone is Teva's glatiramer acetate treatment for relapsing forms of multiple sclerosis. It became one of the company's most recognized specialty medicines and an important part of Teva's U.S. neurology franchise. Its commercial position has been affected by generic competition and changing multiple-sclerosis treatment patterns.

• AjovyMigraine prevention2018

  Ajovy is a fremanezumab medicine used for the preventive treatment of migraine in adults. It is part of Teva's specialty-neuroscience portfolio and is offered in dosing options intended to support different treatment preferences and clinical situations.

• AustedoMovement-disorder therapy2017

  Austedo is a deutetrabenazine product used for certain hyperkinetic movement disorders, including tardive dyskinesia and chorea associated with Huntington's disease. It represents Teva's specialty focus in central nervous system and movement-disorder medicines.

• ProAir HFARespiratory medicine

  ProAir HFA is an albuterol sulfate inhalation aerosol used to treat or prevent bronchospasm in patients with reversible obstructive airway disease. It has been one of the better-known respiratory products associated with Teva's U.S. business, although product ownership, presentation, and market availability should be verified against current U.S. labeling.

• 2017Restructuring and portfolio prioritizationStrategy

  Teva faced generic-drug price pressure, integration demands, and a substantial debt burden after its expansion.

  What changed. The company announced cost reductions, organizational changes, portfolio reviews, and a stronger emphasis on financial resilience and selected specialty medicines.

  Aftermath. The program reshaped Teva's global operations, including its U.S. business, although the company continued to maintain broad generic and specialty offerings.

  Source
• 2016Acquisition of Actavis GenericsM&A

  Teva sought to increase scale and broaden its generic-drug portfolio through the purchase of Allergan's Actavis Generics business.

  What changed. Teva completed the acquisition and integrated a substantially larger generic-pharmaceutical operation.

  Aftermath. The deal expanded Teva's international and U.S. presence but contributed to leverage and integration pressures that were followed by restructuring and portfolio-prioritization measures.

  Source

• 2022U.S. opioid litigation settlementsControversy

  Teva reached a nationwide framework and subsequent state agreements addressing claims by U.S. governmental entities concerning the marketing and distribution of opioids. The arrangements included monetary and in-kind commitments; Teva stated that the settlements did not admit wrongdoing.

  Source

• 2017Teva announces broad restructuring and cost-reduction program

  Following the expansion of its generic portfolio and increased financial pressure, Teva announced a global restructuring intended to reduce costs, simplify operations, and strengthen its balance sheet.

  Other
  Source
• 2016Teva completes acquisition of Actavis Generics

  Teva completed its acquisition of Allergan's generic pharmaceuticals business, creating a substantially larger global generic-drug platform with major implications for its U.S. operations.

  M&A
  Source

1. Teva Pharmaceuticals USA
2. Teva Pharmaceutical Industries investor relations
3. Teva Pharmaceutical Industries annual reports and filings
4. U.S. Food and Drug Administration
5. Actavis Generics acquisition completed
6. Teva expands COVID-19 response activities